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Abstract
Background: Since little is known about chronic kidney disease (CKD) among people living with HIV/AIDS
(PLWHA) in Sub-Saharan Africa, the prevalence and nature of CKD were assessed in Burundi through a multicenter
cross-sectional study.
Methods: Patients underwent assessments at baseline and 3 months later. Glomerular Filtration Rate (GFR) was
estimated using abbreviated 4-variable Modification of Diet in Renal Diseases (MDRD) and Cockroft-Gault
estimation methods. Patients were classified at month 3 into various CKD stages using the National Kidney
Foundation (NKF) definition, which combines GFR and urinary abnormalities. Risk factors for presence of proteinuria
(PRO) and aseptic leukocyturia (LEU) were further analyzed using multiple logistic regression.
Results: Median age of the patients in the study (N = 300) was 40 years, 70.3% were female and 71.7% were on
highly active antiretroviral therapy. Using the MDRD method, CKD prevalence in patients was 45.7%, 30.2% of
whom being classified as stage 1 according to the NKF classification, 13.5% as stage 2 and 2% as stage 3. No
patient was classified as stage 4 or 5. Among CKD patients with urinary abnormality, PRO accounted for 6.1% and
LEU for 18.4%. Significant associations were found between LEU and non-steroidal anti-inflammatory drug (NSAID)
use, previous history of tuberculosis, low body mass index and female gender and between PRO and high viral
load.
Conclusion: Our study, using a very sensitive definition for CKD evaluation, suggests a potentially high prevalence
of CKD among PLWHA in Burundi. Patients should be regularly monitored and preventative measures
implemented, such as monitoring NSAID use and adjustment of drug dosages according to body weight. Urine
dipsticks could be used as a screening tool to detect patients at risk of renal impairment.
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Background
S i n c et h ee r ao fh i g h l ya c t i v ea n t i r e t r o v i r a lt h e r a p y
(HAART), mortality and morbidity among HIV-infected
patients in high-income countries have dramatically
shifted from opportunistic infections (OI) to chronic
conditions [1]. Since 1995 in the United States, chronic
kidney diseases (CKD) have become the fourth leading
cause of mortality among HIV-infected patients [2].
In resource-limited countries, while OI still account
for the majority of HIV-related mortality and morbidity,
their incidence is likely to decline, paralleling the con-
tinued implementation of earlier and wider access to
HAART. OI will be replaced by chronic diseases, includ-
ing CKD, as a consequence of longer survival [3].
Patients from Sub-Saharan Africa (SSA) are of particular
concern, since they accumulate CKD risk factors both
related to HIV (late HIV diagnosis, OI, nephrotoxic OI-
or HIV-related drugs) and non-related (hypertension,
diabetes and ethnicity) [4-7].
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despite being the area hardest hit by the pandemic. Data
that is available on CKD prevalence in PLWHA ranges
from 6% to 45%, although a variety of definitions have
been used [7-11].
In Burundi, CKD data are inexistent, both in the gen-
eral population and among PLWHA. We assessed the
prevalence of CKD among PLWHA in Burundi through
a multicenter cross-sectional study. We also assessed
risk factors related to CKD among PLWHA in order to
draw recommendations in terms of monitoring.
Methods
A multicenter cross-sectional survey was conducted
between February 2008 and February 2009 in 4 outpati-
ent HIV-clinics in Bujumbura, Burundi.
All HIV1 positive adults above the age of 18 who
attended the clinics for routine visits during the survey
period were included, until the predefined objective of
300 patients (75 patients per site) was reached. The
assumptions underlying the calculation of the sample
size were that 250 000 persons were HIV positive in
Burundi, at least 12% of whom having CKD, based on
the literature reviewed at that time [12-14]. The mea-
surement error was set at +/- 4%, leading to a required
253 patients, to whom we added an extra 20% to
account for the expected lost to follow-up percentage,
leading to a total of 300 patients.
Patients were assessed at baseline and 3 months later
for those identified as possible CKD-patients at baseline.
Baseline parameters were as follows: socio-demographic,
medical and therapeutic histories; physical assessments
including weight, height and blood pressure; blood
examinations including CD4 cell count, HIV1 viral load,
serum creatinine (auto-creatinine Liquicolor
®,H u m a n ,
Wiesbaden, Germany; result expressed in μmol/l), hepa-
titis C and B (HBs antigen) serologies; and urinalysis
using a dipstick. At month 3, possible CKD-patients
were reassessed through physical examination, serum
creatinine measurement and urine dipstick. Upon this
reassessment, those classified as CKD-patients under-
went further blood examination, consisting of serum
levels of sodium, potassium, uric acid, bicarbonates,
phosphorus, and patients diagnosed with glycosuria
underwent serum glycemia in order to discriminate dia-
betes mellitus.
Urine samples were assessed for the presence of pro-
tein, blood, leucocytes, nitrite and glucose using dip-
sticks (Multistix 8SG
®, Bayer Diagnostics, Salisbury,
United Kingdom) and results were analyzed by an auto-
matic analyzer (Clinitek Status
®, Bayer Diagnostics, Sal-
isbury, United Kingdom) to ensure standardization.
Proteinuria, leukocyturia, hematuria and glycosuria were
measured in a semi-quantitative way (0; 1 + to 3 +),
whereas nitrite was simply measured in terms of
absence or presence.
The Glomerular Filtration Rate (GFR) was estimated
by 2 methods: a) abbreviated 4-variable Modification of
Diet in Renal Disease (MDRD) [GFRMDRD (ml/min/1.73
m
2) = 186.3 (serum creatinine/88.4)
-1.154 (age
-0.203)
(0.742 if female) (1.212 if of African origin)] [15]; b)
Cockroft-Gault (CG) [GFRCG (ml/min) = {(140 - age)
(weight)(1.23 if male or 1.04 if female)(1.18 if of African
origin)}/serum creatinine] [16]. Serum creatinine was
measured in μmol/l.
The definition and classification of CKD were based
on the National Kidney Foundation (NKF) guidelines
[15]. Accordingly, the definition of possible CKD at
baseline was: GFRCG <6 0m l / m i no rG F R MDRD <6 0
ml/min/1.73 m
2 and/or kidney damage defined as a
urinary abnormality at any GFR level. In addition to
proteinuria, which was the most evidence-based marker
of kidney damage according to NKF, 2 other markers
were included, leukocyturia and hematuria. Urinary
abnormality was defined by isolated proteinuria ≥ 1+ or
isolated hematuria ≥ 2+ or isolated leukocyturia ≥ 2+ or
the association of hematuria ≥ 1+ with leukocyturia ≥ 1
+o rp r o t e i n u r i a≥ 1+. Patients with urine dipstick
abnormalities as described above at baseline underwent
a urine bacterial examination. If a urinary tract infection
was diagnosed, the patient was prescribed an appropri-
ate antibiotic and urine samples were again assessed by
dipstick 10 days after the completion of treatment, in
order to both confirm the disappearance of the urine
infection and reassess urinary abnormalities. If leukocy-
turia persisted, the patient was screened for symptoms
of active tuberculosis.
Patients were classified as CKD if GFRCG <6 0m l /
min, GFRMDRD < 60 ml/min/1.73 m
2,o ri fu r i n a r y
abnormalities persisted at month 3 after the baseline
assessment.
In addition, persistent abnormalities as highlighted by
urine dipstick at month 3 were categorized into 5
groups (a-e): a) proteinuria (PRO) in case of either iso-
lated proteinuria ≥ 3+ or proteinuria ≥ 1+ associated
with hematuria ≥ 2+ or leukocyturia ≥ 2+; b) leukocy-
turia (LEU) in case of leukocyturia ≥ 2+, isolated or not,
without proteinuria; c) hematuria (HEM) in case of iso-
lated hematuria ≥ 2+; d) glycosuria (GLY) in case of
normoglycemic glycosuria; e) any other combination of
abnormalities (i.e. proteinuria ≥ 1+ but < 3+, isolated or
associated with hematuria or leukocyturia = 1+) was
classified as “other”.
Due to local constraints, it was not possible to per-
form ultrasonographic examination or renal biopsy in
patients diagnosed with CKD.
Stata version 8 (Stata corporation, College Station,
Texas, USA) was used for all statistical analyses. We
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GFR, using the 2 methods of measure, CG and MDRD.
Prevalences of CKD were calculated together with their
95% confidence intervals, after checking the normality
of their distribution. Lost to follow-up patients were
considered as either being all affected by CKD or none
being affected, to provide upper and lower estimates of
CKD prevalence as part of the sensitivity analysis. As
CKD is a mixture of multiple etiologies, we focused on
the analysis of abnormalities as highlighted by the use of
urine dipsticks. Patients with glycosuria, related to either
pregnancy or diabetes mellitus, were excluded from the
risk factor analysis, as were patients with known causes
of CKD, namely diabetes and hypertension.
Predictors of PRO and LEU were analyzed, using a
univariable analysis and multivariable logistic regression
model. Numerical variables were included as continuous
variables after verifying their normality, otherwise they
were used as categorized variables. Variables associated
with PRO or LEU, with a p-value < 0.2 in univariate
analysis, were included in a multivariable analysis. The
most parsimonious final model was determined by using
a stepwise method, while variables were also removed
when statistical interactions with a biological explana-
tion were present (e.g. between WHO stage and a his-
tory of tuberculosis).
When comparing GFRMDRD and GFRCG,w ea d j u s t e d
GFRCG for the body surface area (BSA), using the
Dubois formula [17]: BSA adjusted GFRCG =( G F R CG ×
1.73)/BSA, with BSA (m
2)=( w e i g h t
0.425 ×h e i g h t
0.725)
× 0.007184 (weight in kilograms, height in centimeters).
We then computed Pearson’s correlation coefficient and
used the Bland-Altman method to compute the agree-
ment between the BSA adjusted GFRCG and GFRMDRD.
The kappa index was used to analyze the level of agree-
ment between the NKF stages classification obtained
using GFRMDRD and GFRCG. Agreement was considered
“moderate” when the index values ranged from 0.41 to
0.60, “good” for values ranging from 0.61 to 0.80 and
“excellent” for values from 0.81 to 1.
T h es t u d yw a sa p p r o v e db yt h eN a t i o n a lE t h i c sC o m -
mittee of Burundi. Before inclusion in the study, patients
were informed and asked to sign a study consent form
in Kirundi, the local language. Abnormal results were
forwarded to the physician in charge, such that appro-
priate decisions could be taken.
Results
A total of 300 patients were included, 75 patients from
each of the 4 HIV-clinics. Patient flow is summarized in
Figure 1. Baseline data are provided in Table 1. All
patients were African, the median age was 40.1 years
old and 70.3% were women. Median CD4 cell count was
325 cells/mm
3 (IQR 205-502). Two hundred and five
patients (69.8%) were on HAART, with a median dura-
tion of 1 year (IQR 1-3) and 47.9% had previously been
treated with non-steroidal anti-inflammatory drugs
(NSAID). Among those on HAART, 78% were receiving
the WHO recommended regimen (consisting of AZT +
3TC + NVP 28.8%, AZT + 3TC + EFV 10.7%, D4T +
3TC + NVP 27.8%, D4T + 3TC + EFV 10.7%) and the
remaining 22% were receiving various other drugs,
including 5 patients on tenofovir and one on indinavir.
At baseline, median GFRMDRD was 99.7 ml/minute/
1.73m
2 and median GFRCG was 111 ml/min.
Among the 300 patients, 215 were identified at base-
l i n ea sp o s s i b l eC K D - p a t i e n t sa c c o r d i n gt ot h eN K F
definition and consequently were eligible for the second
assessment 3 months later. Eighty-five patients were
classified at baseline as non-CKD and did not undergo
the month 3 assessment. Out of the 215 possible CKD-
patients, 51 were loss to follow-up and 4 patients died
leading to 160 possible-CKD patients at the time of the
month 3 assessment.
After the month 3 assessment, the prevalence of CKD
was 45.7% (N = 112, 95% CI [39.7-51.7]) using the
MDRD estimation method and 46.5% (N = 114, 95% CI
[40.3-52.7]) using the CG estimation method, out of the
final study population of 245 patients. Fourteen patients
had urinary tract infections at baseline and received
antibiotics. No patient with glycosuria was diagnosed
with pregnancy, and no urinary tuberculosis was diag-
nosed among patients with aseptic leukocyturia. Eight
women were pregnant, two patients were taking isonia-
zid prophylaxis and five patients were using tenofovir.
Patient classification according to the NKF CKD
stages is provided in Table 2. Urinary abnormalities
with normal GFR were found in 74 patients (30.2%)
according to the MDRD estimation and in 65 patients
(26.5%) according to the CG estimation (stage 1). Thirty
three (13.5%) and 5 (2%) patients were respectively clas-
sified at stages 2 and 3 of the NKF classification, using
the MDRD estimation. Using the CG estimation, 37
patients (15.1%) were classified at stage 2 and 12
patients (4.9%) at stage 3. No patient was classified at
stages 4 or 5.
Out of the 245 remaining patients, 110 had persistent
urinary abnormalities. Abnormalities were classified
LEU in 18.4% of cases (95% CI [13.1-23.2], N = 45),
PRO in 6.1% (95% CI [3.1-9.1], N = 15), HEM in 3.3%
(95% CI [1.0-5.5], N = 8) and “other” in 17.1% (95% CI
[12.4-21.9], N = 42). No GLY was detected.
Five patients with CKD from hypertension or diabetes
were excluded for the purpose of the risk factor analysis.
Results of univariable and multivariable analysis for risk
factors of LEU are shown in Tables 3 and 4. Using the uni-
variable analysis, the following factors were all associated
with LEU: previous use of aminoglycosides, NSAID and
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viral load, low Body Mass Index (BMI), low CD4 cell
count, female gender and a previous history of tuberculo-
sis. Risk factors of LEU, in multivariable analysis, were as
follows: female gender (OR = 6, 95% CI [2.0-18.0], p <
0.01), a previous history of tuberculosis (OR = 2.9, 95% CI
[1.4-6.0], p < 0.01), a history of NSAID use (OR = 2.2, 95%
CI [1.0-4.6], p = 0.03) and low BMI (OR = 0.8 per 0.1 kg/
m
2 increment, 95% CI [0.8-0.9], p = 0.01). Pregnancy was
not associated with LEU.
Patients fulfilling inclusion 
criteria 






























    
 















Questionnaire, physical examination, blood 
pressure, weight and height measurement, 
CD4 cell and viral load count, serum 
creatinine measurement and urine dipstick  
Estimation of Glomerular Filtration Rate with 
MDRD and Cockroft-Gault (CG) methods 
 Urine dipstick analysis 
No CKD  
(N = 85) 
Possible CKD  
(N = 215) 
GFR estimation, urine dipstick 
analysis 
(N = 160) 
CKD  
(N= 112 with MDRD method, 
114 with CG method) 
*Abnormal: 




isolated proteinuria >1+,  
or isolated hematuria > 2+,  
or isolated leukocyturia >2+  
or the association of hematuria 
>1+ with leukocyturia >1+ or with 
protenuria >1+    
No CKD  
(N= 48 with MDRD method, 
46 with CG method) 
- 51 loss of 
follow-up 
- 4 deaths 
Figure 1 flowchart of included patients.
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in Tables 5 and 6. In the univariable analysis, PRO was
significantly associated with the current HAART use and
high viral load. In the multivariable analysis, PRO only
remained associated with a viral load higher than 3.3
log10 copies/ml (OR = 7.7, 95% CI [1.9-30.5], p < 0.01).
The results of the sensitivity analysis were as follows:
if loss to follow-up patients were all classified as CKD
(according to the MDRD method), or as non-CKD,
prevalence of CKD would have been 55.6% and 37%
respectively.
The Pearson’s correlation coefficient between BSA
adjusted GFRCG and GFRMDRD was 0.91. The Bland Alt-
man method provided a mean difference of -1.7 ml/
min/1.73 m
2 between BSA adjusted GFRCG and
GFRMDRD [95% CI -3.7 to -0.3]. The kappa index of
agreement between the NKF stages classification, based
on either GFRMDRD or GFRCG was 0.79.
Table 1 Descriptive analysis of the 300 included patients at baseline
Variables Estimates N Missing information (N)
Socio-demographic factors
Age (years), median (IQR) 40.1 (33-46.5) 0
Female, % (95% CI) 70.3 (65-75) 211 0
Body mass index (kg/m
2), median (IQR) 21.8 (19.3-24.2) 7
HIV-related factors
CD4 (cells/mm3), median (IQR) 325 (205-502) 14
Viral load (log10 copies/ml), median (IQR) 1.65 (< 1.6-3.1) 11
Current use of HAART, % (95% CI) 69.8 (65.5-75.0) 205 3
Current use of cotrimoxazole, % (95% CI) 87 (82-90) 260 0
History of tuberculosis, % (95% CI) 39.2 (33.7-45) 117 2
Kidney risk factors
History of diabetes, % (95% CI) 2.0 (0.7-4.3) 6 2
History of hypertension*, % (95% CI) 2.7 (1.1-5.2) 8 1
Positive hepatitis B serology, % (95% CI) 5.0 (2.7-8.2) 14 19
Positive Hepatitis C serology, % (95% CI) 5.3 (3.0-8.6) 15 20
History of aminoglycosides use, % (95% CI) 8.7 (5.6-12.8) 23 37
History of NSAID use, % (95% CI) 47.9 (42-54) 135 18
Renal functions
GFR Cockroft-Gault (ml/min), median (IQR) 99.7 (79-126) 0
GFR MDRD (ml/min/1.73 m
2), median (IQR) 111 (88-138) 0
IQR, Inter Quartile Range; 95% CI, 95% Confidence Interval; HAART, Highly Active Antiretroviral Therapy; NSAID, Non Steroidal Anti-Inflammatory Drugs; GFR,
Glomerular Filtration Rate; MDRD, Modification of Diet in Renal Disease
* TAS > 16 or TAD > 10 at physical assessment or a previous history of hypertension.
Table 2 Chronic Kidney Disease stages according to the National Kidney Foundation), using Cockroft Gault and
Modification of Diet in Renal Disease Glomerular Filtration Rate estimations (N = 245¤)
CKD stage GFR estimation
(ml/min/1.73 m
2 if MDRD, ml/min if CG)
MDRD estimation CG estimation
N%N %
0 ≥ 90, without urine dipstick abnormality 133 54.3 131 53.4
1 ≥ 90, with urine dipstick abnormality* 74 30.2 65 26.5
2 60-89, with urine dipstick abnormality* 33 13.5 37 15.1
3 30-59, with or without urine dipstick abnormality* 5 2.0 12 4.9
4 15-29, with or without urine dipstick abnormality* 0 0 0 0
5 < 15, with or without urine dipstick abnormality* 0 0 0 0
Total 245 100 245 100
* urine dipstick abnormalities:
- Proteinuria ≥ 1+,
- Isolated hematuria or leukocyturia ≥ 2+
- Hematuria ≥ 1+ associated with leukocyturia ≥ 1+
CKD, Chronic Kidney Disease; GFR, Glomerular Filtration Rate; MDRD, Modification of Diet in Renal Disease; CG, Cockroft-Gault
¤ 245 assessable patients = 85 non CKD patients at baseline + 160 assessable patients at month 3
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N LEU (N) OR 95% CI p
Age (1 year increment) 0.9 0.9-1.0 0.59
Gender Male 63 4 1
Female 133 40 4.7 1.6-13.8 < 0.01
History of tuberculosis No 144 18 1
Yes 95 25 2.5 1.3-4.9 < 0.01
Hepatitis B positive No 215 38 1
Yes 12 2 1.0 0.2-5.1 0.93
Hepatitis C positive No 213 37 1
Yes 13 3 0.7 0.2-2.7 0.60
Body Mass index (0.1 kg/m
2 increment) 0.9 0.8-0.9 0.03
History of NSAID use No 116 15 1
Yes 110 29 2.4 1.2-4.8 0.01
Current use of Cotrimoxazole No 53 2 1
Yes 181 42 7.7 1.8-33.3 < 0.01
Current use of HAART No 67 7 1
Yes 171 37 2.3 0.9-5.6 0.05
Viral load (log10 copies/ml) < 1.6 122 29 1
[1.6-3.3] 59 8 0.5 0.2-1.2
[3.3-8] 49 7 0.5 0.2-1.3 0.15
History of aminoglycosides use No 191 12 1
Yes 19 7 2.7 0.9-7.3 0.05
History of acyclovir use No 162 27
Yes 59 17 2.0 1.0-4.1 0.04
WHO stage 1 36 2 1
2 48 8 3.7 0.7-18.5
3 122 25 4.4 0.9-19.5
4 28 9 8.0 1.6-41.1 0.03
CD4 (1 cell/mm
3 increment) 0.9 0.9-1.0 0.06
LEU, Leukocyturia; OR, Odds Ratio; 95% CI, 95% Confidence Interval; HAART, Highly Active Antiretroviral Therapy; NSAID, Non Steroidal Anti-Inflammatory Drugs;
WHO, World Health Organization;
Table 4 Multivariable analysis of risk factors for











History of tuberculosis No 1
Yes 2.9 1.4-6.0 <
0.01




History of NSAID use No 1
Yes 2.2 1.0-4.6 0.03
OR, Odds Ratio; 95% CI, 95% Confidence Interval; NSAID, Non Steroidal Anti-
Inflammatory Drugs;
¤ multivariable analysis with 221 patients without missing data among the
240 assessable patients




OR 95% CI p
Age (1 year increment) 0.9 0.9-1.0 0.12
Gender Male 67 5 1
Female 173 10 0.8 0.2-2.3 0.63
CD4 (1 cell/mm
3 increment) 0.9 0.9-1.0 0.44
Hepatitis B positive No 215 14 1
Yes 12 1 0.8 0.1-6.3 0.80
Hepatitis C positive No 213 14 1
Yes 13 1 0.8 0.1-7.0 0.87
Current HAART No 67 8 1
Yes 171 7 0.3 0.1-0.9 0.03
Viral load (log10 copies/ml) < 1.6 122 3 1
[1.6-3.3] 59 4 2.9 0.6-13.3
[3.3-3.8] 49 8 7.7 1.9-30.6 < 0.01
PRO, Proteinuria; OR, Odds Ratio, 95% CI, 95% Confidence Interval, HAART,
Highly Active Antiretroviral Therapy
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The prevalence of CKD among this population of
PLWHA in Burundi accounted for nearly half of the
sample: 45.7% using the MDRD method and 46.5%
using the CG method. LEU was more frequently identi-
fied than PRO, accounting for 18.4% and 6.1%,
respectively.
This prevalence of CKD is one of the highest ever
found among both resource-rich and resource-limited
countries [8,9,11,18,19]. It might be related to the use of
the new and sensitive, but less specific definition of
CKD, incorporating urinary abnormalities [15]. A sensi-
t i v eb u tl e s ss p e c i f i ct o o lm i g h tb eu s e da sas c r e e n i n g
tool to detect patients at risk of developing renal impair-
ment and needing careful renal monitoring. Cross-stu-
dies’ comparison of CKD prevalence is hampered by the
heterogeneity of definitions used, such as chronic kidney
failure with a GFRCG below 60 ml/min or a combination
of definitions assessing thep r e s e n c eo fp r o t e i n u r i a
together or not with the GFR [8,9,11,18]. The only study
using the same definition as that presented here was
performed in the USA. In that case a CKD prevalence
of 23.7% was reported using a once-off measurement of
creatinine [19].
Patients at NKF stage 3 (with GFRMDRD <6 0m l / m i n /
1.73 m
2) represented 2% of our sample, using the
MDRD estimation and 4.9% using the CG estimation.
Quite similar rates were found in Kenya and Spain, 4.8%
[11] and 7.6% [20], respectively. Patients with GFRMDRD
< 90 ml/min/1.73 m
2 represented 15.5% in our sample.
Overton et al. reported a much higher prevalence of
43% in the United States, but hypertensive patients were
included in their sample and constituted 33% of their
population [21]. A study carried out in Uganda showed
that the proportion of patients with GFRCG < 60 ml/min
was 12% at baseline and decreased with HAART to 4%,
after 24 months of follow up [10]. This latter rate is
similar to our study, where 4.9% of patients had GFRCG
< 60 ml/min and could be linked to the fact that the
majority of our patients (71.7%) were on HAART.
Indeed, Kalayjian et al. reported significant GFR
improvement following HAART prescription, supporting
the hypothesis that kidney inflammation is secondary to
immune activation [22]. In the DART trial conducted in
Uganda and Zimbabwe, investigators reported a moder-
ately decreased median GFR (30-60 ml/min) in 7% of
the patients using the CG formula and 3% using the
MDRD formula (adjusted for ethnicity), close to the
4.9% and 2% found in our study, even though urinary
abnormalities were not taken into account [23].
The presence of LEU could be interpreted as a marker
of interstitial nephritis. The association between a his-
tory of tuberculosis and LEU (OR = 2.91) possibly
reflects sequelae of the urological extension of tubercu-
losis which is common but underdiagnosed [24]. In our
sample, the proportion of patients with a history of
tuberculosis was very high (39.2%). Those patients may
have had urological extension of tuberculosis and may
have had secondarily developed leukocyturia. In Bur-
undi, the availability of tuberculosis diagnosis tools such
as mycobacterial culture is limited. The association of
LEU and NSAID is not surprising. Interstitial nephritis
has been reported after exposure to NSAID with leuko-
cyturia tending to last from a month to a year [25]. The
mechanism and risk factors of NSAID toxicity have not
yet been clearly identified [25]. NSAID may also aggra-
vate previously damaged kidneys. In South Africa,
Fabian et al screened 585 HAART-naïve PLWHA for
urinary abnormalities, using a once-off dipstick and
reported leukocyturia in 30.3% of the patients, 70.9% of
whom were sterile [26]. The authors hypothesized that
this could be caused by interstitial nephritis, either due
to HIV-infection or to drug toxicity.
In our sample, an increase in BMI was negatively
associated with the presence of LEU (OR = 0.8 per 0.1
kg/m
2 increment). In Burundi, adjusting dosages to
body weight is not always possible. Consequently,
patients with a low BMI are exposed to a greater con-
centration of drugs and therefore to acute tubular
necrosis, with sequellar interstitial damage (e.g. with
aminoglycosides). In our results, the use of aminoglyco-
sides was associated with the presence of LEU in uni-
variable analysis, but due certainly to a lack of power,
the association did not remain in the multivariable ana-
lysis. Association between low BMI and renal impair-
ment was also reported in Nigeria. This was explained
as being due to an advanced renal disease [8]. However,
in our sample, the stage of renal impairment was not
advanced enough for the association to be interpreted in
this way. Hepatitis C has also been associated with pro-
t e i n u r i ai nt h el i t e r a t u r e[ 2 7 ] ,b u to u rs a m p l es i z ep r e -
vented us from detecting such an association.
The association between PRO and high viral load may
reflect the presence of HIV associated nephropathy
(HIVAN). Prevalence of HIVAN at the time of the study
was estimated at between 3.5% and 12%, the highest
rates coming from autopsy-based estimations [28].
Table 6 Multivariable analysis of risk factors for
proteinuria (N¤ = 230)





[3.3-3.8] 7.7 1.9-30.6 < 0.01
OR, Odds Ratio; 95% CI, 95% Confidence Interval
¤ multivariable analysis with 230 patients without missing data among the
240 assessable patients
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resource-rich countries, a change in the epidemiology of
CKD is being reported. HIVAN is progressively being
replaced by other CKD mechanisms, such as arterione-
phrosclerosis [29] and drug-related toxicity [19]. In our
sample, the low prevalence of PRO could be related to
the fact that nearly half of the patients had undetectable
VL. The genetic susceptibility to HIVAN, through the
gene MYH9 may also be different in this part of SSA, as
suggested by other studies in East Africa, where the pre-
valence of HIVAN was low [11,18].
In our sample, both correlation and agreement
between GFRMDRD and GFRCG were good. Buitrago et
al found a moderate level of agreement (kappa index of
0.55) but focused on agreement for CKD at stage 3,
which was underrepresented in our sample [30]. The
MDRD method tended to slightly overestimate the GFR
compared with the CG method, as suggested by the
negative mean difference, though this was not statisti-
cally significant. The overestimation of GFR by MDRD
compared with CG was also reported in the DART trial.
In our population, the proportions of underweight (BMI
< 18.5) and obese (BMI > 30) persons were 6% and 17%
respectively, similar to those in the DART trial (respec-
tively 5% and 18%), supporting the hypothesis that
weight distribution had an influence on the MDRD/CG
estimations. We also agree with our colleagues that the
use of MDRD and CG formulas require further valida-
tion for East Africa, based on comparison with a refer-
ence technique of GFR measurement [11,23].
We acknowledge several limitations to our study, due
to the challenges of performing specialized examinations
in Burundi. The great difficulty in performing ultra-
sound measurements and renal biopsies prevented pre-
cise diagnosis of patients diagnosed with GFR and/or
urine dipstick abnormalities. We therefore used urinary
abnormality as a tool to categorize patients and dis-
cussed possible diagnosis linked to them. Among female
patients, chronic pyelonephritis or asymptomatic bacter-
ial urinary tract infections could have been underdiag-
nosed due to a low quality of bacteriological
examination, especially for those on cotrimoxazole. This
could have led to an overestimation of CKD prevalence
and could partly explain the association between female
gender and LEU. Tuberculosis may also have been
underdiagnosed, but none of the patients presented with
clinical signs of active disease. The presence of leukocy-
turia and hematuria might also be related to genito-
urinary diseases other than tuberculosis or urinary tract
infections. Underdiagnosis of these infections might
have led to an overestimation of CKD prevalence in our
sample. The baseline kidney status of the non-HIV
population is largely unknown in Burundi and we can-
not attribute kidney function abnormalities to HIV-
related factors with certitude. Similarly, the Dubois
equation was used although the relevance of this equa-
tion in this population is unknown. Despite these biases,
we believe the results of this study are important in
helping raise awareness of CKD among PLWHA in this
context.
Conclusions
Whereas previous studies mainly focused on HIVAN,
there is now a need to shift towards a more comprehen-
sive review of all the potential risk factors associated
with CKD. HIV is a chronic disease and patients are
now exposed to a range of non HIV-specific kidney risk
factors, such as arteriosclerosis, hypertension or diabetes
mellitus. In addition, PLWHA are more likely to experi-
ence kidney damage, due to a higher susceptibility to
renal infections including tuberculosis, to longer and
more frequent exposure to multiple drugs, HIV-related
or not, and finally due to inflammation. Thus, diagnos-
ing HIV earlier could lead to earlier HAART prescrip-
tion, as recently recommended by the WHO [31]. This
could also help decrease the incidence of tuberculosis
and therefore urological sequelae. Further context-speci-
fic studies are required as well as comprehensive care
for PLWHA, including kidney risk factors assessments
and weight-adjusted prescriptions. NSAID use, either
upon prescription or over-the-counter, should be closely
monitored. The increasing use of tenofovir-based regi-
mens is also of concern, as incomplete reversibility of
renal toxicity has been reported, mitigated by other
reassuring preliminary results [32-34]. The use of a sen-
sitive but less specific definition of CKD, such as that
used in this study, might help to detect patients at risk
of both developing a GFR decrease and further renal
impairment. In the context of Burundi and most
resource-limited countries, the use of a urine dipstick as
a screening test may be easily implemented as part of
the routine monitoring of PLWHA. Further studies with
long-term follow-up are needed to analyze the renal
outcome of patients diagnosed as CKD using this sensi-
tive definition.
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